Arcus Biosciences Inc. Overview

Arcus Biosciences, Inc., a biotechnology company based in Hayward, United States, specializes in the discovery, development, and commercialization of immunotherapies aimed at treating cancer patients. The company serves its customers nationwide and is listed on the New York Stock Exchange. Arcus Biosciences went public on March 15, 2018, and more information about their operations and initiatives can be found on their website at www.arcusbio.com .

Recent Stock Performance

In recent months, Arcus Biosciences has experienced notable fluctuations in its stock price. Over the past year, the stock has ranged from a low of $6.5 to a high of $18.98. As of April 30, 2025, the closing price was $8.62. Despite these fluctuations, the company’s market capitalization stands at approximately $890.49 million USD.

Financial Metrics

The company’s financial metrics present a mixed picture. The price-to-earnings (P/E) ratio is currently at -2.71, which indicates that the company is not yet profitable. Meanwhile, the price-to-book (P/B) ratio is 1.6, suggesting that the market values the company at 1.6 times its book value. These figures highlight the complexity of Arcus Biosciences’ valuation and underscore the need for a deeper analysis of its financial health and future prospects.

Conclusion

Arcus Biosciences continues to focus on its core mission of developing innovative cancer treatments through immunotherapy. While the company’s stock has seen recent volatility, its market cap and financial ratios suggest a nuanced valuation landscape. Investors and stakeholders may benefit from a thorough examination of the company’s financials and strategic initiatives to better understand its potential in the biotechnology sector.